度伐利尤单抗对比安慰剂联合放化疗治疗局部晚期宫颈癌(CALLA):一项随机、双盲、3期试验
CALLA研究在15国105家医院入组770例局部晚期宫颈癌患者,随机接受度伐利尤单抗或安慰剂联合放化疗。中位随访约18.5个月,两组中位无进展生存期均未达到(HR 0.84,95%CI 0.65-1.08,P=0.17),12个月无进展生存率度伐利尤单抗组76.0% vs 安慰剂组73.3%。度伐利尤单抗耐受性良好,但未在生物标志物未选择的全人群中显著改善无进展生存期。
要点
- 度伐利尤单抗联合放化疗未显著改善局部晚期宫颈癌全人群的无进展生存期(HR 0.84,95%CI 0.65-1.08,P=0.17)。
- 12个月无进展生存率度伐利尤单抗组76.0% vs 安慰剂组73.3%。
- 度伐利尤单抗组治疗相关死亡5例,安慰剂组1例。
核心结论
- 度伐利尤单抗同步联合放化疗在局部晚期宫颈癌患者中耐受性良好,但未在生物标志物未选择的全人群中显著改善无进展生存期。
- 作者认为同步度伐利尤单抗联合放化疗值得在肿瘤PD-L1高表达患者中进一步探索。
研究设计与样本
- CALLA为随机、双盲、3期试验,纳入15个国家105家医院的患者。
- 入组标准为年龄≥18岁、既往未治疗的局部晚期宫颈癌(腺癌、鳞癌或腺鳞癌;FIGO 2009分期IB2-IIB淋巴结阳性或≥III期任何淋巴结状态),ECOG体能状态0或1。
- 770例女性按1:1随机分配至度伐利尤单抗组(385例)或安慰剂组(385例),中位年龄49岁(IQR 41-57)。
- 度伐利尤单抗1500 mg静脉给药每4周一次,联合并紧随放化疗后给药,最多24个周期。
- 放化疗包括45 Gy外照射放疗每周5次,同步顺铂40 mg/m2或卡铂AUC 2每周一次共5周,随后行图像引导近距离放疗(高剂量率27.5-30 Gy或低剂量/脉冲剂量率35-40 Gy)。
主要发现
- 度伐利尤单抗组中位随访18.5个月(IQR 13.2-21.5),安慰剂组18.4个月(IQR 13.2-23.7)。
- 两组中位无进展生存期均未达到(95%CI未达到-未达到),HR 0.84(95%CI 0.65-1.08;P=0.17)。
- 12个月无进展生存率度伐利尤单抗组76.0%(71.3-80.0)vs 安慰剂组73.3%(68.4-77.5)。
- 最常见的3-4级不良事件为贫血(度伐利尤单抗组76/385例[20%] vs 安慰剂组56/384例[15%])和白细胞减少(39例[10%] vs 49例[13%])。
- 严重不良事件发生于度伐利尤单抗组106例(28%)和安慰剂组89例(23%);治疗相关死亡度伐利尤单抗组5例(尿路感染、失血性贫血、肺栓塞各1例仅与放化疗相关;内分泌疾病1例仅与度伐利尤单抗相关;脓毒症1例与度伐利尤单抗和放化疗均相关),安慰剂组1例(肺炎与放化疗相关)。
关键数值与推荐
- 主要终点为研究者按RECIST v1.1评估的意向治疗人群无进展生存期。
- 安全性在至少接受一剂研究治疗的患者中评估。
临床怎么用
- 作者认为同步度伐利尤单抗联合放化疗值得在肿瘤PD-L1高表达患者中进一步探索。
- 原文未据此给出常规临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concurrent chemoradiotherapy has been the standard of care for locally advanced cervical cancer for over 20 years; however, 30-40% of treated patients have recurrence or progression within 5 years. Immune checkpoint inhibition has improved outcomes for patients with PD-L1 positive metastatic or recurrent cervical cancer. We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer. METHODS: The CALLA randomised, double-blind, phase 3 trial included 105 hospitals across 15 countries. Patients aged at least 18 years with previously untreated locally advanced cervical cancer (adenocarcinoma, squamous, or adenosquamous; International Federation of Gynaecology and Obstetrics [FIGO] 2009 stage IB2-IIB lymph node positive, stage ≥III any lymph node status) and WHO or Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (1:1) through an interactive web response system using a permuted block size of 4 to receive durvalumab (1500 mg intravenously once every 4 weeks) or placebo with and following chemoradiotherapy, for up to 24 cycles. Chemoradiotherapy included 45 Gy external beam radiotherapy at 5 fractions per week concurrent with intravenous cisplatin (40 mg/m2) or carboplatin (area under the concentration-time curve 2) once weekly for 5 weeks, followed by image-guided brachytherapy (high-dose rate, 27·5-30 Gy or low-dose/pulse-dose rate, 35-40 Gy). Randomisation was stratified by disease stage status (FIGO stage and node status) and geographical region. Chemoradiotherapy quality was continuously reviewed. The primary endpoint was progression-free survival, assessed by the investigator using Response Evaluation Criteria in Solid Tumors, version 1.1, in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03830866. FINDINGS: Between Feb 15, 2019, and Dec 10, 2020, 770 women were randomly assigned (385 to durvalumab and 385 to placebo; median age 49 years [IQR 41-57]). Median follow-up was 18·5 months (IQR 13·2-21·5) in the durvalumab group and 18·4 months (13·2-23·7) in the placebo group. At data cutoff, median progression-free survival had not been reached (95% CI not reached-not reached) for either group (HR 0·84; 95% CI 0·65-1·08; p=0·17); 12-month progression-free survival was 76·0% (71·3-80·0) with durvalumab and 73·3% (68·4-77·5) with placebo. The most frequently reported grade 3-4 adverse events in both groups were anaemia (76 [20%] of 385 in the durvalumab group vs 56 [15%] of 384 in the placebo group) and decreased white blood cells (39 [10%] vs 49 [13%]). Serious adverse events occurred for 106 (28%) patients who received durvalumab and 89 (23%) patients who received placebo. There were five treatment-related deaths in the durvalumab group (one case each of urinary tract infection, blood loss anaemia, and pulmonary embolism related to chemoradiotherapy only; one case of endocrine disorder related to durvalumab only; and one case of sepsis related to both durvalumab and chemoradiotherapy). There was one treatment-related death in the placebo group (pneumonia related to chemoradiotherapy). INTERPRETATION: Durvalumab concurrent with chemoradiotherapy was well tolerated in participants with locally advanced cervical cancer, however it did not significantly improve progression-free survival in a biomarker unselected, all-comers population. Concurrent durvalumab plus chemoradiotherapy warrants further exploration in patients with high tumoral PD-L1 expression. Rigorous monitoring ensured high chemoradiotherapy compliance with advanced technology and allowed patients to receive optimal care. FUNDING: AstraZeneca.
引用
- Monk BJ, Toita T, Wu X, et al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023. PMID: 38039991. doi:10.1016/S1470-2045(23)00479-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。